Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Advarra Inc.

Neither a doctor nor a teaching hospital

Research payments

$1,028,018

218 payments

Through program year 2025, Advarra Inc. is reported as receiving $1,028,018 in research payments, across 218 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $17,495 3
2024 Research $876,525 153
2023 Research $129,364 57
2022 Research $4,324 3
2019 Research $310 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $997,029 207 payments
  2. Celgene Corporation $16,520 2 payments
  3. Exelixis Inc. $12,854 5 payments
  4. Medtronic, Inc. $1,305 2 payments
  5. Straumann USA LLC $310 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis $428,160 52 payments
  2. A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis $419,310 70 payments
  3. A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis $36,365 21 payments
  4. A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy $31,556 9 payments
  5. A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) $31,351 8 payments
  6. Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease (TargetTau-1) $27,335 40 payments
  7. A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer $22,182 6 payments
  8. Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release $16,190 1 payment
  9. Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors $12,854 5 payments
  10. Expand II $1,305 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record